A Trans-amplifying RNA Simplified to Essential Elements is Highly Replicative and Robustly Immunogenic in Mice

Overview

Journal Mol Ther

Publisher Cell Press

Specialties Molecular Biology
Pharmacology

Date 2023 Jan 25

PMID 36694464

Authors

Mario Perkovic

Stefanie Gawletta

Tina Hempel

Silke Brill

Evelin Nett

Ugur Sahin

Tim Beissert

Affiliations

Soon will be listed here.

Abstract

Trans-amplifying RNA (taRNA) is a split-vector derivative of self-amplifying RNA (saRNA) and a promising vaccine platform. taRNA combines a non-replicating mRNA encoding an alphaviral replicase and a transreplicon (TR) RNA coding for the antigen. Upon translation, the replicase amplifies the antigen-coding TR, thereby requiring minimal amounts of TR for immunization. TR amplification by the replicase follows a complex mechanism orchestrated by genomic and subgenomic promoters (SGPs) and generates genomic and subgenomic amplicons whereby only the latter are translated into therapeutic proteins. This complexity merits simplification to improve the platform. Here, we eliminated the SGP and redesigned the 5' untranslated region to shorten the TR (STR), thereby enabling translation of the remaining genomic amplicon. We then applied a directed evolution approach to select for faster replicating STRs. The resulting evolved STR (eSTR) had acquired A-rich 5' extensions, which improved taRNA expression thanks to accelerated replication. Consequently, we reduced the minimal required TR amount by more than 10-fold without losing taRNA expression in vitro. Accordingly, eSTR-immunized mice developed greater antibody titers to taRNA-encoded influenza HA than TR-immunized mice. In summary, this work points the way for further optimization of taRNA by combining rational design and directed evolution.

Citing Articles

Alphaviral backbone of self-amplifying RNA enhances protein expression and immunogenicity against SARS-CoV-2 antigen.

Casmil I, Bathula N, Huang C, Wayne C, Cairns E, Friesen J Mol Ther. 2025; 33(2):514-528.

PMID: 39741413 PMC: 11852984. DOI: 10.1016/j.ymthe.2024.12.055.

mRNA vaccines as cancer therapies.

Huang S, Que H, Wang M, Wei X Chin Med J (Engl). 2024; 137(24):2979-2995.

PMID: 39668413 PMC: 11706586. DOI: 10.1097/CM9.0000000000003455.

mRNA vaccines for infectious diseases - advances, challenges and opportunities.

Pardi N, Krammer F Nat Rev Drug Discov. 2024; 23(11):838-861.

PMID: 39367276 DOI: 10.1038/s41573-024-01042-y.

1mΨ influences the performance of various positive-stranded RNA virus-based replicons.

Miyazato P, Noguchi T, Ogawa F, Sugimoto T, Fauzyah Y, Sasaki R Sci Rep. 2024; 14(1):17634.

PMID: 39085360 PMC: 11292005. DOI: 10.1038/s41598-024-68617-y.

-amplifying RNA hitting new grounds: Gene regulation by microRNA.

Lundstrom K Mol Ther Nucleic Acids. 2024; 35(2):102191.

PMID: 38725441 PMC: 11078691. DOI: 10.1016/j.omtn.2024.102191.

References

Frolov I, Hardy R, Rice C . Cis-acting RNA elements at the 5' end of Sindbis virus genome RNA regulate minus- and plus-strand RNA synthesis. RNA. 2001; 7(11):1638-51. PMC: 1370205. DOI: 10.1017/s135583820101010x. View

Bloom K, van den Berg F, Arbuthnot P . Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 2020; 28(3-4):117-129. PMC: 7580817. DOI: 10.1038/s41434-020-00204-y. View

Lundstrom K . Self-Replicating RNA Viruses for Vaccine Development against Infectious Diseases and Cancer. Vaccines (Basel). 2021; 9(10). PMC: 8541504. DOI: 10.3390/vaccines9101187. View

Blakney A, McKay P, Bouton C, Hu K, Samnuan K, Shattock R . Innate Inhibiting Proteins Enhance Expression and Immunogenicity of Self-Amplifying RNA. Mol Ther. 2020; 29(3):1174-1185. PMC: 7935664. DOI: 10.1016/j.ymthe.2020.11.011. View

Orlandini von Niessen A, Poleganov M, Rechner C, Plaschke A, Kranz L, Fesser S . Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3' UTRs Identified by Cellular Library Screening. Mol Ther. 2019; 27(4):824-836. PMC: 6453560. DOI: 10.1016/j.ymthe.2018.12.011. View

Vogel A, Lambert L, Kinnear E, Busse D, Erbar S, Reuter K . Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses. Mol Ther. 2017; 26(2):446-455. PMC: 5835025. DOI: 10.1016/j.ymthe.2017.11.017. View

Fuller D, Berglund P . Amplifying RNA Vaccine Development. N Engl J Med. 2020; 382(25):2469-2471. DOI: 10.1056/NEJMcibr2009737. View

Kuhn A, Diken M, Kreiter S, Selmi A, Kowalska J, Jemielity J . Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Ther. 2010; 17(8):961-71. DOI: 10.1038/gt.2010.52. View

Rozen-Gagnon K, Stapleford K, Mongelli V, Blanc H, Failloux A, Saleh M . Alphavirus mutator variants present host-specific defects and attenuation in mammalian and insect models. PLoS Pathog. 2014; 10(1):e1003877. PMC: 3894214. DOI: 10.1371/journal.ppat.1003877. View

10.

Kumar A, Blum J, Le T, Havelange N, Magini D, Yoon I . The mRNA vaccine development landscape for infectious diseases. Nat Rev Drug Discov. 2022; 21(5):333-334. DOI: 10.1038/d41573-022-00035-z. View

11.

Beissert T, Perkovic M, Vogel A, Erbar S, Walzer K, Hempel T . A Trans-amplifying RNA Vaccine Strategy for Induction of Potent Protective Immunity. Mol Ther. 2019; 28(1):119-128. PMC: 6953774. DOI: 10.1016/j.ymthe.2019.09.009. View

12.

Simon-Loriere E, Schwartz O . Towards SARS-CoV-2 serotypes?. Nat Rev Microbiol. 2022; 20(4):187-188. PMC: 8855751. DOI: 10.1038/s41579-022-00708-x. View

13.

Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27):2603-2615. PMC: 7745181. DOI: 10.1056/NEJMoa2034577. View

14.

Lello L, Utt A, Bartholomeeusen K, Wang S, Rausalu K, Kendall C . Cross-utilisation of template RNAs by alphavirus replicases. PLoS Pathog. 2020; 16(9):e1008825. PMC: 7498090. DOI: 10.1371/journal.ppat.1008825. View

15.

Kreiter S, Konrad T, Sester M, Huber C, Tureci O, Sahin U . Simultaneous ex vivo quantification of antigen-specific CD4+ and CD8+ T cell responses using in vitro transcribed RNA. Cancer Immunol Immunother. 2007; 56(10):1577-87. PMC: 11029841. DOI: 10.1007/s00262-007-0302-7. View

16.

Zhu Y, Machleder E, Chenchik A, Li R, Siebert P . Reverse transcriptase template switching: a SMART approach for full-length cDNA library construction. Biotechniques. 2001; 30(4):892-7. DOI: 10.2144/01304pf02. View

17.

Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, Huber C . Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood. 2006; 108(13):4009-17. DOI: 10.1182/blood-2006-04-015024. View

18.

Grudzien-Nogalska E, Jemielity J, Kowalska J, Darzynkiewicz E, Rhoads R . Phosphorothioate cap analogs stabilize mRNA and increase translational efficiency in mammalian cells. RNA. 2007; 13(10):1745-55. PMC: 1986804. DOI: 10.1261/rna.701307. View

19.

Beissert T, Koste L, Perkovic M, Walzer K, Erbar S, Selmi A . Improvement of In Vivo Expression of Genes Delivered by Self-Amplifying RNA Using Vaccinia Virus Immune Evasion Proteins. Hum Gene Ther. 2017; 28(12):1138-1146. PMC: 5737720. DOI: 10.1089/hum.2017.121. View

20.

Kis Z, Kontoravdi C, Shattock R, Shah N . Resources, Production Scales and Time Required for Producing RNA Vaccines for the Global Pandemic Demand. Vaccines (Basel). 2020; 9(1). PMC: 7824664. DOI: 10.3390/vaccines9010003. View